tldrdailynews.com logo

"Pfizer's Bold Move: Revitalizing Investor Interest with New Cancer Drugs"

1 min read
Source: STAT
"Pfizer's Bold Move: Revitalizing Investor Interest with New Cancer Drugs"
Photo: STAT
TL;DR

Pfizer is facing a significant challenge as its shares have plummeted, and it aims to address this by focusing on new cancer drugs, including the recent acquisition of Seagen for $43 billion. The company's executives are holding an investor briefing to persuade shareholders of the potential payoff. CEO Albert Bourla is adamant about the deal's potential, despite the market's skepticism.

Topics:businessbusiness-healthcare#business-healthcare#cancer-treatment#investor-briefing#market-capitalization#pfizer#pharmaceutical-industry
Share this article
  1. Pfizer is about to make a big push in cancer. Will investors listen?  STAT
  2. Pfizer eyes 8 blockbuster cancer drugs in new oncology plan  FiercePharma
  3. After COVID decline, Pfizer builds out cancer pipeline and leans into ADCs  Fierce Biotech
  4. Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth  Yahoo Finance
  5. Pfizer highlights cancer drugs it thinks could reignite investor interest - STAT  STAT

Want the full story? Read the original reporting

Read on STAT